New
BPC 5 mg + TB 5 mg
54,00 €
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
Description
BPC 5 mg + TB 5 mg (Combination)
Healing / Recovery
MECHANISM OF ACTION
A synergistic combination that harnesses the localized activation of the VEGF/NO pathway by BPC-157, along with the systemic sequestration of actin and the promotion of cell migration associated with TB-500. BPC-157 initiates localized angiogenesis and tissue matrix repair; TB-500 recruits progenitor cells and modulates systemic inflammation.
KEY BENEFITS
- Faster soft tissue repair than with any of the peptides alone.
- Coverage for localized repair (BPC-157) and systemic repair (TB-500).
- Reduction of inflammation and pain following an injury.
- Recovery of joints, tendons, ligaments, and muscles.
- A convenient, single-vial protocol for injury recovery.
SIDE EFFECTS AND SAFETY
Review the individual ingredients. The additive tolerability profile remains favorable.
RESEARCH AND CLINICAL NOTES
The rationale for the combination is based on complementary mechanisms. There are no direct randomized clinical trials of the combination, but the mechanistic synergy is well established.
TARGET PROFILE:
Sports medicine, orthopedics, physical therapy, and active aging programs.
Additional information
| Weight | ,26 kg |
|---|
Related products
New
BPC 157
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Accelerated healing of tendons, ligaments, muscles, and connective tissue.
- Protection of the gastrointestinal mucosa and support for ulcer healing.
- Neuroprotection and peripheral nerve regeneration.
- Powerful anti-inflammatory action through the suppression of pro-inflammatory cytokines.
- Systemic cytoprotective effects on multiple organ systems.
- Benefits at SNC: Research on depression, PTSD, and addictive behavior.
New
GHK-Cu
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A significant increase in collagen synthesis and improved skin firmness.
- Accelerated healing and reduced scarring.
- Stimulation of the hair follicle and improvement in hair density.
- Systemic anti-aging effect through modulation of gene expression.
- Systemic antioxidant and anti-inflammatory action.
- Bone Regeneration and Nerve Repair in Research Models.
Ipamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- A clean GH surge with no side effects associated with cortisol or prolactin.
- Increased lean muscle mass and fat loss.
- Improved sleep quality and recovery.
- Regulation of intestinal motility, with application in ileus.
- Ideal for long-term use due to its selectivity profile.
- Reference for use in combination with CJC-1295 without DAC.
New
Kisspeptin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- It stimulates the LH surge to optimize testosterone levels in men.
- Activation of the HPG axis without suppression by exogenous testosterone.
- Improvement of libido via the central dopaminergic pathway.
- Supporting fertility through GnRH pulse restoration.
- Potential in hypogonadotropic hypogonadism.
- Emerging: Support for cardiac collagen and neuroprotection.
MOTS-c
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- AMPK-mediated metabolic improvements, including glucose and fat utilization.
- Mimetic properties of exercise.
- Anti-inflammatory and anti-aging effects.
- Supports bone metabolism through osteoblastic activity.
- Protection against age-related physical decline.
- Potential for research on T2DM and obesity management.
New
NAD+
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Optimization of cellular energy and efficiency in ATP production.
- Activation of sirtuins for the epigenetic regulation of longevity.
- Repair of DNA damage through PARP activation.
- Improved mitochondrial biogenesis.
- Cognitive clarity and support for neurological function.
- Applications in research on addiction and depression.
New
Selank
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Rapid anxiolytic effect without sedation or dependence.
- Cognitive improvement: memory consolidation and processing speed.
- Mood stabilization and resilience to stress.
- Modulation of the immune system through tuftsin activity.
- Minimal side effects compared to benzodiazepines.
- Used clinically in Russia to treat anxiety and cognitive disorders.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
